nach oben

Die Urologie

Erschienen in:

27.04.2016 | Nierenkarzinom | Behandlung von Nebenwirkungen

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie

Fatigue und Hypothyreose

verfasst von: D. Sikic, G. Lüdecke, V. Lieb, PD Dr. med. B. Keck

Erschienen in: Die Urologie | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Einsatz von Tyrosinkinaseinhibitoren (TKI) in der Therapie des metastasierten Nierenzellkarzinoms hat nicht nur die Behandlungsstrategie bei dieser Erkrankung grundlegend verändert, sondern stellt den behandelnden Arzt durch das Auftreten typischer Nebenwirkungen vor neue Herausforderungen. Fatigue und Hypothyreose sind zwei häufige Nebenwirkungen der TKI-Therapie, welche häufig auch gemeinsam auftreten können und durch die Beeinträchtigung der Lebensqualität des Patienten nicht selten zum Abbruch der Therapie führen können. Mit dieser Übersichtsarbeit wollen wir dem behandelnden Arzt eine Übersicht über die Klassifikation sowie die stadiengerechten Maßnahmen der therapieassoziierten Fatigue und Hypothyreose darstellen, um Therapieeffektivität und Compliance beim Patienten zu maximieren.

Berger AM, Mooney K, Alvarez-Perez A et al (2015) Cancer-Related Fatigue. J Natl Compr Canc Netw 13:1012–1039 (Version 2.2015)PubMed

Deutsches Krebsforschungszentrum (2015) Krebsinformationsdienst. www.krebsinformationsdienst.de/leben/fatigue/fatigue-index.php. Zugegriffen: 19. November

Ryan JL, Carroll JK, Ryan EP, Mustian KM, Morrow FKGR (2007) Mechanisms of cancer-related fatigue. Oncologist 12(Suppl 1):22–34CrossRefPubMed

Kollmannsberger C, Soulieres D, Wong R, Scalera A, Bjarnason GRG (2007) Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1:41–54

NCI Common Terminology Criteria for Adverse Events (CTCAE) v.3.0 data file.

NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4.0 data file.

Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590CrossRefPubMedPubMedCentral

Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068CrossRefPubMed

Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939CrossRefPubMed

10.

Choueiri TK, Escudier B, Powles T et al (2015) Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373:1814–1823CrossRefPubMed

11.

Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318CrossRefPubMed

12.

Cella D, Davis MP, Négrier S et al (2014) Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. Cancer 120:1871–1880CrossRefPubMed

13.

Cella D, Jensen SE, Hahn EA et al (2014) Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. Cancer Med 3:1353–1358CrossRefPubMedPubMedCentral

14.

Kollmannsberger C, Bjarnason G, Burnett P et al (2011) Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 16:543–553CrossRefPubMedPubMedCentral

15.

Santoni M, Conti A, Massari F et al (2015) Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer 136:1–10CrossRefPubMed

16.

Hutson TE, Bellmunt J, Porta C et al (2010) Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 46:2432–2440CrossRefPubMed

17.

Li Y, Qu GZ-HX-J (2015) The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol 116:216–221CrossRefPubMed

18.

Larkin J, Fishman M, Wood L et al (2014) Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. Am J Clin Oncol 37:397–403CrossRefPubMed

19.

Horneber M, Fischer I, Dimeo F, Weis RJUJ (2012) Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int 109:161–171 (quiz 72)PubMedPubMedCentral

20.

Schmidinger M, Ravaud LJA (2012) Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 4:253–265CrossRefPubMedPubMedCentral

21.

Schmidinger M, Arnold D, Szczylik C, Ravaud WJA (2010) Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 28:856–864CrossRefPubMed

22.

NCCN Guidelines on Cancer-Related Fatigue; Version 2.2015.

23.

Grünwald V, Merseburger KDAS (2010) Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. World J Urol 28:343–351CrossRefPubMed

24.

Suttle AB, Ball HA, Molimard M et al (2014) Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 111:1909–1916CrossRefPubMedPubMedCentral

25.

Houk BE, Bello CL, Poland B, Rosen LS, Motzer DGDRJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357–371CrossRefPubMed

26.

Rini BI, Garrett M, Poland B et al (2013) Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 53:491–504CrossRefPubMedPubMedCentral

27.

Bukowski R, Cella D, Gondek K, Group EBSTCT (2007) Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30:220–227CrossRefPubMed

28.

Pan X, Huang H, Huang Y et al (2015) Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma. Urol Oncol 33:268:e9–15

29.

Fachinformation Votrient®. Juli 2013.

30.

Iyer R, Fetterly G, Sorafenib LATY (2010) a clinical and pharmacologic review. Expert Opin Pharmacother 11:1943–1955CrossRefPubMed

31.

Fachinformation Inlyta®. Mai 2015.

32.

Bianchi L, Rossi L, Tomao F, Papa A, Tomao ZFS (2013) Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocr Relat Cancer 20:R233–45CrossRefPubMed

33.

Garber JR, Cobin RH, Gharib H et al (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22:1200–1235CrossRefPubMed

34.

Wolter P, Stefan C, Decallonne B et al (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448–454CrossRefPubMedPubMedCentral

35.

Mannavola D, Coco P, Vannucchi G et al (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531–3534CrossRefPubMed

36.

Eisen T, Sternberg CN, Robert C et al (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104:93–113CrossRefPubMed

37.

Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731CrossRefPubMed

38.

Tamaskar I, Bukowski R, Elson P et al (2008) Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265–268CrossRefPubMed

39.

Fujiwara Y, Kiyota N, Chayahara N et al (2012) Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs 30:1055–1064CrossRefPubMedPubMedCentral

40.

Torino F, Corsello SM, Longo R, Gasparini BAG (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6:219–228CrossRefPubMed

41.

Di Lorenzo G, Porta C, Bellmunt J et al (2011) Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 59:526–540CrossRefPubMed

Titel: Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie
Fatigue und Hypothyreose
verfasst von: D. Sikic
G. Lüdecke
V. Lieb
PD Dr. med. B. Keck
Publikationsdatum: 27.04.2016
Verlag: Springer Berlin Heidelberg
Schlagwörter: Nierenkarzinom
Tyrosinkinaseinhibitoren
Hypothyreose
Nierenkarzinom
Nierenkarzinom
Fatigue
Tyrosinkinaseinhibitoren
Axitinib
Cabozantinib
Pazopanib
Sorafenib
Sunitinib
Erschienen in: Die Urologie / Ausgabe 5/2016
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-016-0088-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie

Fatigue und Hypothyreose

Zusammenfassung

Das könnte Sie auch interessieren